Literature DB >> 11339805

Hyperglycemia and the O-GlcNAc transferase in rat aortic smooth muscle cells: elevated expression and altered patterns of O-GlcNAcylation.

Y Akimoto1, L K Kreppel, H Hirano, G W Hart.   

Abstract

Hyperglycemia leads to vascular disease specific to diabetes mellitus. This pathology, which results from abnormal proliferation of smooth muscle cells in arterial walls, may lead to cataract, renal failure, and atherosclerosis. The hexosamine biosynthetic pathway is exquisitely responsive to glucose concentration and plays an important role in glucose-induced insulin resistance. UDP-GlcNAc: polypeptide O-N-acetylglucosaminyltransferase (O-GlcNAc transferase; OGTase) catalyzes the O-linked attachment of single GlcNAc moieties to serine and threonine residues on many cytosolic or nuclear proteins. Polyclonal antibody against OGTase was used to examine the expression of OGTase in rat aorta and aortic smooth muscle (RASM) cells. OGTase enzymatic activity and expression at the mRNA and protein levels were determined in RASM cells cultured at normal (5 mM) and at high (20 mM) glucose concentrations. OGTase mRNA and protein are expressed in both endothelial cells and smooth muscle cells in the aorta of normal rats. In both cell types, the nucleus is intensely stained, while the cytoplasm stains diffusely. Immunoelectron microscopy shows that OGTase is localized to euchromatin and around the myofilaments of smooth muscle cells. In RASM cells grown in 5 mM glucose, OGTase is also located mainly in the nucleus. Hyperglycemic RASM cells also display a relative increase in OGTase's p78 subunit and an overall increase protein and activity for OGTase. Biochemical analyses show that hyperglycemia qualitatively and quantitatively alters the glycosylation or expression of many O-GlcNAc-modified proteins in the nucleus. These results suggest that the abnormal O-GlcNAc modification of intracellular proteins may be involved in glucose toxicity to vascular tissues. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11339805     DOI: 10.1006/abbi.2001.2331

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  20 in total

Review 1.  The roles of O-linked β-N-acetylglucosamine in cardiovascular physiology and disease.

Authors:  Natasha E Zachara
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-01-27       Impact factor: 4.733

2.  The paradoxical world of protein O-GlcNAcylation: a novel effector of cardiovascular (dys)function.

Authors:  Susan A Marsh; John C Chatham
Journal:  Cardiovasc Res       Date:  2010-12-21       Impact factor: 10.787

3.  Microarray analysis reveals novel gene expression changes associated with erectile dysfunction in diabetic rats.

Authors:  Chris J Sullivan; Thomas H Teal; Ian P Luttrell; Khoa B Tran; Mette A Peters; Hunter Wessells
Journal:  Physiol Genomics       Date:  2005-08-23       Impact factor: 3.107

Review 4.  Oxidative stress and diabetic complications.

Authors:  Ferdinando Giacco; Michael Brownlee
Journal:  Circ Res       Date:  2010-10-29       Impact factor: 17.367

Review 5.  Nutrient regulation of signaling and transcription.

Authors:  Gerald W Hart
Journal:  J Biol Chem       Date:  2019-01-09       Impact factor: 5.157

Review 6.  Too sweet to resist: Control of immune cell function by O-GlcNAcylation.

Authors:  Tristan de Jesus; Sudhanshu Shukla; Parameswaran Ramakrishnan
Journal:  Cell Immunol       Date:  2018-06-02       Impact factor: 4.868

7.  High glucose induces mitochondrial dysfunction independently of protein O-GlcNAcylation.

Authors:  Sujith Dassanayaka; Ryan D Readnower; Joshua K Salabei; Bethany W Long; Allison L Aird; Yu-Ting Zheng; Senthilkumar Muthusamy; Heberty T Facundo; Bradford G Hill; Steven P Jones
Journal:  Biochem J       Date:  2015-04-01       Impact factor: 3.857

Review 8.  O-GlcNAc and the cardiovascular system.

Authors:  Sujith Dassanayaka; Steven P Jones
Journal:  Pharmacol Ther       Date:  2013-11-25       Impact factor: 12.310

9.  O-GlcNAc Modification: Friend or Foe in Diabetic Cardiovascular Disease.

Authors:  Udayakumar Karunakaran; Nam Ho Jeoung
Journal:  Korean Diabetes J       Date:  2010-08-31

10.  Elevation of Global O-GlcNAc in rodents using a selective O-GlcNAcase inhibitor does not cause insulin resistance or perturb glucohomeostasis.

Authors:  Matthew S Macauley; Xiaoyang Shan; Scott A Yuzwa; Tracey M Gloster; David J Vocadlo
Journal:  Chem Biol       Date:  2010-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.